MarketVIEW: Cytomegalovirus vaccines

$ 9 995 - June 2012 - by VacZine Analytics Group Of Assay Advantage Ltd - 60

Summary

Table of Contents

View Report

Search Inside

Industry

Drug and Medication

Country

World
United Kingdom
Europe
Japan
Germany
France
Italy
Spain
Canada
United States

Keywords

Vaccine

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted, which in turn are influenced by vaccine mechanism of action and vaccinee serostatus.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Executive summary
CMV preconception vaccine: available market ($000s) to 2035
CMV transplant vaccine: available market ($000s) to 2035
CMV preconception vaccine: demand (000s doses) to 2035
CMV transplant vaccine: demand (000s doses) to 2035
CMV vaccine: modelling assumptions/rationale
The role of CMV vaccine(s)
Target populations: CMV preconception vaccine
Target populations: CMV transplant vaccine
Target groups by serological risk profile
Pricing: CMV preconception vaccine
Pricing: CMV transplant vaccine
Target product profile: CMV preconception vaccine
Target product profile: CMV transplant vaccine
Key commercial model assumptions: preconception vaccine
Key commercial model assumptions: transplant vaccine
Markets included in the model
Model forecast comparisons: June 2010 v current
CMV vaccines: R&D pipeline
Competitor landscape: overview
Vical/Astellas: TransVax and CyMVectin
GSK: preconception CMV vaccine
Novartis/AlphaVax: alphavirus replicon CMV vaccine
Sanofi Pasteur: CMV gB vaccine
Other vaccine candidates
Vaccine pipeline summary
Estimated launch dates
CMV: review of current epidemiology
Epidemiology: transplants
Epidemiology: congenital CMV infection
Methodology: HSCTs populations (by age and serostatus)
Methodology: solid organ transplant populations (by age and serostatus)
Methodology: preconception vaccine
Preconception vaccine: comparison of “low” versus “high” coverage scenarios
References/bibliography
About VacZine Analytics
Disclaimer
PAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Title sheet
Scenarion definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME – HIGH
VALUE SUMMARY
VOLUME SUMMARY
Preconception vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Transplant vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Source material
HSCTs by serostatus
Forecast HSCTs
Forecast HSCTs
Kidney and Liver TX base
Forecast Kidney TX
Forecast liver Tx
SOT by serostatus
Populations
Back page
About VacZine Analytics
Disclaimer

BUY THIS REPORT

ASK INFO SPECIALIST 24/7

Alison - online now

00 1 718 618 48 97

Send Message @Alison

Global Drug And Medication Industry : Latest Reports

Vaccines - Global Markets Package

$ 24 060
Industry report
May 2013
by Global Research & Data Services

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The studies provide essential market ...

Infertility Drugs And Devices Market - Global Industry Analysis, Size, Share And Forecast, 2010 - 2017

$ 4 395
Industry report
November 2013
by Transparency Market Research

This report is an effort to identify factors, which will be the driving force for the infertility drugs and devices market and sub-markets in the next few years. The report provides an extensive analysis ...

Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides

$ 5 175
Industry report
March 2013
by Bioseeker

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three ...

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Angiogenesis A ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Breast Cancer, Angiogenes ...

March 2013 $ 5 175

More Reports:

Drug and Medication in China (129)

Drug and Medication in France (47)

Drug and Medication in Germany (47)

Drug and Medication in Italy (45)

Drug and Medication in Japan (61)

Drug and Medication in Spain (42)

Drug and Me... in the United Kingdom (48)

Drug and Me... in the United States (151)

Company Reports

GlaxoSmithKline P.L.C.

Novartis Inc.

Pfizer Inc.

Johnson And Johnson

GlaxoSmithKline PLC

Eli Lilly And Co.

AstraZeneca PLC

Lilly And Co.

Sanofi-Aventis Senegal

Bristol-Myers Squibb Co.

Global Drug And Medication Industry : Latest Downloads

Drug and Medication Industry Analysis

Industry report
April 2013
53 pages

... Use internally as part of a monthly cleansing regimen for gi health antibiotic, anti-inflammatory, antibacterial, antifungal, antioxidant, anti-parasitic, antiviral, disinfectant candida cleanse ...

Drug and Medication Market Brief

Industry report
April 2013
18 pages

... Antiosteoporosic drugs - casula m, filippi a, flacco e, gambera m, manzoli l, menditto e, orlando v, piccinelli r, tragni e, catapano a. Assessment and potential determinats of compliance and persistence to anti ...

Drug and Medication : Innovation and Technology Trends

Industry report
April 2013
12 pages

... Clinical regulatory toxicology phase i clinical phase ii clinical diabetes inflammation oncology (non-cytotoxic) anti-infectives clotting disorders obesity cns nce pipeline nce pipeline tyrosine-tzd, non ...